BillionToOne

Bull case

• BillionToOne is well positioned because its QCT platform powers differentiated, single-molecule ultrasensitive assays that have already produced strong commercial traction in prenatal testing and oncology, including Q2 prenatal volumes of ~181k, Northstar Select’s ~50% higher actionable mutation detection, and payer coverage reaching ~300 million lives.
• Its fundamentals remain impressive, with Q1'26 revenue of $108.4M, 73% gross margin, 16% GAAP operating margin, 24% adjusted EBITDA margin, and $537M of cash, showing that growth is being achieved with best-in-class profitability and balance-sheet strength.
• The outlook is further supported by new catalysts such as UNITY Confirm, the planned MRD launch by YE'26 or in 2H'26, ahead-of-plan sales hiring, and Epic Aura integration, which together should expand utilization and support growth beyond near-term payor timing noise.

Bear case

BillionToOne is facing a fundamentals-driven negative setup because Q2’26 operating expenses of $72M rose faster than revenue, pushing Adj. EBITDA to $16.1M and GAAP EPS to $0.15 below expectations despite $109.4M of revenue and 70% gross margin. Management’s decision to accelerate sales hiring, including 70 reps in 1H’26, pressured near-term profitability and led to lower forecasted margins and higher 2026-2028 operating expenses even as revenue guidance was reaffirmed. The company also faces meaningful structural risks from reimbursement dependence, billing complexity, legal/IP challenges, and intense competition across prenatal, therapy selection, MRD, and early-detection markets.